Hinge Health Inc. (NYSE:HNGE) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Moderate Buy consensus: 19 analysts cover Hinge Health with an average rating of "Moderate Buy" (16 buy, 1 strong buy, 1 hold, 1 sell) and a mean 1‑year target of $67.40, with several firms raising targets into the $63–$95 range.
• Q1 beat and stronger outlook: Hinge reported $0.45 EPS vs. $0.12 estimate and $182.3M revenue (+47% YoY), and it raised FY2026 revenue guidance to $798–$804M while launching an FDA‑cleared Enso migraine program.
• Mixed insider/institution activity: Insiders sold roughly 442,670 shares (~$18.8M) in the past three months, even as major institutional investors (e.g., BIT Capital, Vanguard, Tiger Global) significantly increased their stakes.

Hinge Health Inc. (NYSE:HNGE - Get Free Report) has received an average rating of "Moderate Buy" from the nineteen research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, sixteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $67.40.

Several equities research analysts have recently issued reports on HNGE shares. Piper Sandler reiterated an "overweight" rating and set a $95.00 price target on shares of Hinge Health in a report on Wednesday. Citizens Jmp increased their price target on shares of Hinge Health from $65.00 to $80.00 and gave the stock a "market outperform" rating in a research note on Wednesday. Raymond James Financial reaffirmed an "outperform" rating and issued a $70.00 price objective on shares of Hinge Health in a research note on Wednesday. Wells Fargo & Company raised their target price on Hinge Health from $68.00 to $80.00 and gave the company an "overweight" rating in a report on Wednesday. Finally, Wall Street Zen lowered Hinge Health from a "buy" rating to a "hold" rating in a report on Saturday, May 2nd.

Hinge Health Trading Up 8.8%

HNGE stock opened at $54.15 on Thursday. Hinge Health has a one year low of $30.08 and a one year high of $62.18. The firm has a 50-day moving average of $42.51 and a two-hundred day moving average of $43.96. The firm has a market capitalization of $4.26 billion and a PE ratio of -4.39.

Hinge Health (NYSE:HNGE - Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.33. The company had revenue of $182.31 million for the quarter. Hinge Health had a negative net margin of 78.95% and a negative return on equity of 279.39%. Hinge Health's revenue for the quarter was up 47.2% compared to the same quarter last year. During the same period last year, the firm earned $1.30 earnings per share. On average, equities research analysts anticipate that Hinge Health will post 0.78 earnings per share for the current year.

Key Headlines Impacting Hinge Health

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q1 results beat expectations: $0.45 EPS vs. $0.12 estimate and $182.3M revenue (up 47%), with better margins and stronger client growth driving an after‑hours rally. HNGE Stock Up on Q1 Earnings & Revenue Beat, 2026 Outlook Improved
• Positive Sentiment: Company raised FY2026 revenue outlook to $798M–$804M (well above the prior consensus) and raised Q2 revenue guide to ~$194M–$196M — indicating stronger-than-expected growth this year. Hinge Health forecasts $798M-$804M 2026 revenue while launching FDA-cleared Enso migraine program
• Positive Sentiment: Product expansion: Hinge launched an FDA‑cleared Enso migraine program, widening its digital therapeutic portfolio and opening a new addressable market that could support long‑term revenue growth. Hinge Health forecasts $798M-$804M 2026 revenue while launching FDA-cleared Enso migraine program
• Positive Sentiment: Analyst momentum: Multiple firms raised price targets and ratings (Stifel, Citizens/JMP, Wells Fargo, Needham), with several targets now in the $63–$80 range — a bullish signal that reinforces investor optimism. Benzinga Analyst Coverage
• Neutral Sentiment: Full earnings materials and call transcript are available for investors who want detail on assumptions, margin leverage and client metrics. Hinge Health Lifts Outlook on Strong 1Q, Sees Long Runway for Expansion

Insiders Place Their Bets

In related news, CFO James Budge sold 11,006 shares of the business's stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $42.26, for a total transaction of $465,113.56. Following the transaction, the chief financial officer owned 401,427 shares of the company's stock, valued at approximately $16,964,305.02. The trade was a 2.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman Gabriel M.I. Mecklenburg sold 166,666 shares of the business's stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $45.32, for a total transaction of $7,553,303.12. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 442,670 shares of company stock valued at $18,786,901 in the last three months. 18.92% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hinge Health

Several large investors have recently modified their holdings of the stock. BIT Capital GmbH lifted its position in shares of Hinge Health by 79.3% during the 4th quarter. BIT Capital GmbH now owns 3,316,101 shares of the company's stock worth $154,033,000 after buying an additional 1,466,577 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Hinge Health by 110.5% during the fourth quarter. Vanguard Group Inc. now owns 2,605,532 shares of the company's stock valued at $121,027,000 after acquiring an additional 1,367,693 shares during the period. Tiger Global Management LLC boosted its stake in shares of Hinge Health by 227.1% in the 4th quarter. Tiger Global Management LLC now owns 1,805,751 shares of the company's stock valued at $83,877,000 after purchasing an additional 1,253,743 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Hinge Health in the 4th quarter worth about $54,469,000. Finally, Millennium Management LLC increased its position in shares of Hinge Health by 225.0% during the 4th quarter. Millennium Management LLC now owns 1,479,642 shares of the company's stock worth $68,729,000 after purchasing an additional 1,024,317 shares in the last quarter.

About Hinge Health

Hinge Health NYSE: HNGE is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company's platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.